Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, Francesco Onida
Organisation/Company: University of Milan
Country: Italy
do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

<table>
<thead>
<tr>
<th>Company</th>
<th>Financial Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyowa Kirin</td>
<td>Speaker at a conference entitled: &quot;MAKE A MARK. Sharing experience. I Linfomi di derivazione T-linfocitaria primitivi della cute (Micosi Fungoide &amp; Sindrome di Sézary)&quot; - 16-6-2022</td>
</tr>
<tr>
<td>Takeda</td>
<td>Speaker at a webinar entitled: &quot;Hodgkin Lymphoma and Cutaneous Lymphoma: state of the art and clinical evidences&quot;. 25-3-2021</td>
</tr>
<tr>
<td>Italfarmaco</td>
<td>Speaker at a webinar entitled: &quot;prophylaxis and management of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation&quot; - 20-5-2021</td>
</tr>
<tr>
<td>MEDAC</td>
<td>Speaker in two webinars on the use of treosulfan for the conditioning of patients undergoing allogeneic hematopoietic stem cell transplantation.</td>
</tr>
</tbody>
</table>
2.5 Principal investigator

No interest declared

2.6 Investigator

<table>
<thead>
<tr>
<th>Period</th>
<th>Company</th>
<th>Products</th>
<th>Therapeutic Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/2018-(current)</td>
<td>Shire</td>
<td>Maribavir</td>
<td>Post-HSCT CMV reactivation</td>
</tr>
<tr>
<td>10/2017-02/2020</td>
<td>Incyte</td>
<td>Itacitinib</td>
<td>acute GvHD</td>
</tr>
<tr>
<td>04/2021-(current)</td>
<td>AlloVir Inc.</td>
<td>Viralym-M (ALVR-105)</td>
<td>Virus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplant</td>
</tr>
<tr>
<td>02/2021-(current)</td>
<td>Alexion</td>
<td>Ravulizumab</td>
<td>Thrombotic microangiopathy after hematopoietic stem cell transplant</td>
</tr>
<tr>
<td>12/2021-(current)</td>
<td>Syndax Pharmaceuticals, Inc.</td>
<td>Axatillimab</td>
<td>Recurrent or refractory active chronic graft versus host disease</td>
</tr>
</tbody>
</table>

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

since 2013 Member of Milan (Italy) "Area 2" Ethics Committee

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

Classified as public by the European Medicines Agency

DOI Form Version-number: 4
"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency’s Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

<table>
<thead>
<tr>
<th>Full Name:</th>
<th>Francesco Onida</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date:</td>
<td>2022-08-15</td>
</tr>
</tbody>
</table>

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template